Altimmune (LTS:0A4C) Other Gross PPE : $2.09 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Altimmune Other Gross PPE?

Altimmune's Other Gross PPE for the quarter that ended in Dec. 2024 was $2.09 Mil.

Altimmune's quarterly Other Gross PPE declined from Jun. 2024 ($0.48 Mil) to Sep. 2024 ($0.45 Mil) but then increased from Sep. 2024 ($0.45 Mil) to Dec. 2024 ($2.09 Mil).

Altimmune's annual Other Gross PPE increased from Dec. 2022 ($2.04 Mil) to Dec. 2023 ($2.09 Mil) but then stayed the same from Dec. 2023 ($2.09 Mil) to Dec. 2024 ($2.09 Mil).

Altimmune Other Gross PPE Historical Data

The historical data trend for Altimmune's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altimmune Other Gross PPE Chart

Altimmune Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Gross PPE

Get a 7-Day Free Trial

2.25

2.83

2.04

2.09

Altimmune Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Gross PPE	Get a 7-Day Free Trial															2.09	0.54	0.48	0.45	2.09

Altimmune Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Altimmune Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altimmune Inc (LTS:0A4C) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ALT:USA 3G0:Germany 3G0:Germany

Address

910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878

Website

https://www.altimmune.com

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Altimmune Headlines

No Headlines